Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking. We carried out a meta-analysis in patients with acute schizophrenia to evaluate the efficacy of cariprazine over placebo and active comparators in overall symptoms, positive and negative symptoms and quality of life. Low and high (≥6 mg/day) doses were tested separately. The possible effect of clinical-demographic modulators was also tested. Four studies (2144 patients) were included. Both high and low cariprazine doses proved superior to placebo in all symptom domains. The standardized mean difference (SMD) to placebo showed a modest impact on overall symptoms compared with meta-analytic results for other antipsychotics (SMD was similar to lurasidone, asenapine, ziprasidone and aripiprazole, but lower than risperidone, quetiapine and olanzapine). The SMD to placebo on negative symptoms was superior to many antipsychotics including aripiprazole, with a slightly more relevant effect of cariprazine low doses. This effect was probably on secondary negative symptoms since the short-term follow-up of the studies included. Meta-regression data further refined the compound clinical profile, suggesting that cariprazine may be particularly useful in young patients with a relatively short duration of disease.

中文翻译：

---

Cariprazine特异性特征治疗急性精神分裂症：荟萃分析和荟萃回归的随机对照试验。

Cariprazine是一种新的多巴胺D2和D3受体部分激动剂抗精神病药。缺乏在急性精神分裂症和特定人群中疗效的荟萃分析证据。我们对急性精神分裂症患者进行了荟萃分析，以评估卡比拉嗪优于安慰剂和活性比较剂的总体症状，阳性和阴性症状以及生活质量。低剂量和高剂量（≥6mg /天）分别进行测试。还测试了临床人口统计学调节剂的可能作用。包括四项研究（2144例患者）。在所有症状域中，高和低剂量的卡哌嗪均被证明优于安慰剂。与其他抗精神病药物的荟萃分析结果相比，安慰剂的标准平均差异（SMD）对总体症状影响不大（SMD与卢拉西酮，阿塞那平，齐拉西酮和阿立哌唑，但低于利培酮，喹硫平和奥氮平）。安慰剂对阴性症状的贴片优于包括阿立哌唑在内的许多抗精神病药，低剂量的卡哌嗪的相关性稍强。由于包括对研究的短期随访，这种作用可能是对继发性阴性症状的影响。荟萃回归数据进一步完善了化合物的临床特征，表明卡哌嗪对病程相对较短的年轻患者尤其有用。由于包括对研究的短期随访，这种作用可能是对继发性阴性症状的影响。荟萃回归数据进一步完善了化合物的临床特征，表明卡哌嗪对病程相对较短的年轻患者尤其有用。由于包括对研究的短期随访，这种作用可能是对继发性阴性症状的影响。荟萃回归数据进一步完善了化合物的临床特征，表明卡哌嗪对病程相对较短的年轻患者尤其有用。